Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/20/2007US7297820 Thio substituted stilbene amines; inhibiting the aggregation of amyloid proteins
11/20/2007US7297818 Adamantane derivatives
11/20/2007US7297817 Thio-substituted arylmethanesulfinyl derivatives
11/20/2007US7297808 Statin derivatives
11/20/2007US7297799 Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof
11/20/2007US7297794 Phenoxy amine compounds and compositions for delivering active agents
11/20/2007US7297793 Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
11/20/2007US7297792 Pyrazolopyridines and pyrazolopyridazines as antidiabetics
11/20/2007US7297789 From 4-amino-2-methyl-10H-thieno(2,3-b)(1,5) benzodiazpine HCl and 1-methylpiperazine in an aprotic high boiling solvent; purifying in an acid medium; basifying to pH of 7.5-9; and extracting with a low boiling organic solvent
11/20/2007US7297787 E.g., (2S, 3S, 4R, 5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluoro-phenylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol, by aminating a 6-halopurine ribofuranose nucleoside in the presence of CaCO3 , wherein acid is added to the reaction mixture.
11/20/2007US7297779 An oligonucleotide that inhibits the function or expression of Asef (APC-stimulated guanine nucleotide exchange factor)
11/20/2007US7297716 Enhanced production of blood components, blood cells and plasma without freezing
11/20/2007US7297715 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
11/20/2007US7297714 Inhibitors of cathepsin S
11/20/2007US7297713 Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof
11/20/2007US7297712 Coupling an aliphatic bromide with an aliphatic alkylamine, protecting both terminal primary alcohol groups of aliphatic alcohol, reacting both intermediates, quaternizing the product, passing quaternized product through a chroamtograph
11/20/2007US7297711 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
11/20/2007US7297710 Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
11/20/2007US7297709 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
11/20/2007US7297708 Central nervous system disorders; psychological disorders
11/20/2007US7297707 Selective CB1 G protein coupled receptor antagonists; obesity; such as N-benzothiazol-2-yl-2-chloro-N-(3,4-dimethoxy-phenyl)-4-fluoro-benzamide
11/20/2007US7297706 Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders
11/20/2007US7297705 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
11/20/2007US7297703 Macrolides
11/20/2007US7297702 Administering during follicular phase in a dosage less than an ovulation-inhibiting or abortion-inductive dose; 11 beta -[(4-N,N-Dimethylamino) -phenyl]-17 beta -hydroxy-17 alpha -propinyl-4,9(10)-estradien-3-one (RU 38486) for example; will not abort previously implanted fetus
11/20/2007US7297701 Anti-cancer cyclopenta [G]quinazoline compounds
11/20/2007US7297700 rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions including myocardial infarction, the treatment and prophylaxis of pain syndromes; e.g. 5,6,7,8-Tetrahydro-pyrido[3,4-d]pyrimidine-4-carboxylic acid cyclohexylmethyl-amide
11/20/2007US7297699 Piperazine and piperidine compounds
11/20/2007US7297698 e.g. (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide; antiandrogenic agent
11/20/2007US7297697 4-(diarylmethyl)-1-piperazinyl derivatives
11/20/2007US7297696 Antiarthritic agents; antihistamines; atherosclerosis; multiple sclerosis; Crohn's disease; nephritis; pancreastitis; skin disorders; restenosis; prevent leukocyte migration
11/20/2007US7297695 Anticancer agents; inhibits tyrosine kinase activity of growth factor receptors; antiproliferative agents
11/20/2007US7297694 central nervous system disorders; traumas; anticancer agents; neurodegenerative agents; analgesics; headaches and cardiovascular disorders
11/20/2007US7297693 furan-, pyrrole- or thiophenecarboxamides ring-substituted with a hydroxyimino-fused ring and a nitrogen heteroarene; e.g., 5-[5-(1-Morpholin-4-yl-methanoyl)-2-pyridin-4-yl-furan-3-yl]-indan-1-one oxime;treating neurotraumatic diseases, cancer, neurodegeneration, pain, migraine and cardiac hypertrophy
11/20/2007US7297692 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
11/20/2007US7297691 Administering galanthamine and nicotinic receptors
11/20/2007US7297689 trapping a carbonyl compound; peritoneal dialysate having a reduced carbonyl compound content, degradation products of glucose
11/20/2007US7297688 An oral contraceptive starter kit comprising at least two cycle packs of oral contraceptives containing an estrogen and a progestin, and having penultimate cycle with greater steroid dosage than last cycle pack dosage
11/20/2007US7297687 Method of treating infectious diseases with polysaccharide derivatives
11/20/2007US7297686 complex of chromium, ATP, and cysteine; administered orally or by injection; diabetes
11/20/2007US7297684 breast and prostatic tumors; administration of an antisense oligodeoxynucleotide which is complementary to a portion of the gene encoding insulin-like growth factor binding protein -5
11/20/2007US7297683 Crystalline forms of an antiviral benzimidazole compound
11/20/2007US7297682 liquid crystal diphosphate polymorph; antibacterial and antiprotozoal agents
11/20/2007US7297681 For use in therapy of growth metabolic disorders
11/20/2007US7297680 Mixture comprising sialinated erythropoietin (EPO) for use in generating stable, human, recombinant proteins that are modified post-translationally
11/20/2007US7297523 Human elongase genes and uses thereof
11/20/2007US7297509 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
11/20/2007US7297353 For oral administration, injection and topical application; can eliminate the aseptic inflammations, edema, adhesion caused by aseptic inflammations, and stubborn pain, complex body disorders caused by aseptic inflammation, edema and adhesion
11/20/2007US7297346 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain attention deficit hyperactivity disorder and fatigue
11/20/2007US7297343 Bioactive medical films
11/20/2007US7297330 Low dose haptenized tumor cell and tumor cell extract immunotherapy
11/20/2007US7297325 Hydrophilic light absorbing compositions for determination of physiological function
11/20/2007US7297099 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/20/2007CA2451754C Thienothiazine compounds having anti-inflammatory and analgesic activities and their preparation methods and the use thereof
11/20/2007CA2441549C Ipratropium formulation for pulmonary inhalation
11/20/2007CA2429642C Fused heteroaromatic glucokinase activators
11/20/2007CA2423783C Inhibition of systemic infections in humans and vertebrates by dietary fibers
11/20/2007CA2417843C Administration of an injectable antibiotic in the ear of an animal
11/20/2007CA2378977C Thrombosis filter having a surface treatment
11/20/2007CA2344652C Carboxymethylgalactose derivatives
11/20/2007CA2328197C Methods for treating neuropsychiatric disorders
11/20/2007CA2318138C Vitamin d solution holder and containers for transfusions
11/20/2007CA2316841C Crystallographically stable amorphous cephalosporin compositions and process for producing the same
11/20/2007CA2305598C Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
11/20/2007CA2300289C A pharmaceutical composition active in reducing production of mcp-1 protein
11/20/2007CA2295746C Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols
11/20/2007CA2268600C Topical dmso treatment for palmar-plantar erythrodysesthesia
11/20/2007CA2260926C Illudin analogs useful as antitumor agents
11/20/2007CA2254144C Pharmaceutical compositions based on diclofenac
11/20/2007CA2216372C Oral 2-methyl-thieno-benzodiazepine formulation
11/20/2007CA2214436C Corticosteroid-containing pharmaceutical composition
11/20/2007CA2211389C Novel pharmaceutical combination
11/20/2007CA2206362C Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
11/20/2007CA2204745C Antiparasitic composition for the treatment and protection of pets
11/20/2007CA2171743C Nucleotide analogs
11/20/2007CA2140382C Vitamin d compounds and method of preparing these compounds
11/17/2007CA2587319A1 Cmklr regulation of adipogenesis and adipocyte metabolic function
11/16/2007CA2588656A1 Antimicrobial hand wash formulations
11/16/2007CA2554386A1 Combinations of hmg coa reductase inhibitors and negatively charged phospholipids and uses thereof
11/15/2007WO2007131219A2 Cannabinoid receptor antagonists/inverse agonists
11/15/2007WO2007131193A2 Main chain acid-degradable polymers for the delivery of bioactive materials
11/15/2007WO2007131179A1 Factor xa inhibitors
11/15/2007WO2007131168A2 Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
11/15/2007WO2007131154A2 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
11/15/2007WO2007131113A2 Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury
11/15/2007WO2007131088A2 Oral rehydration compositions
11/15/2007WO2007131072A2 Hydrolytically-resistant boron-containing therapeutics and methods of use
11/15/2007WO2007131047A2 Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
11/15/2007WO2007131041A2 The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
11/15/2007WO2007131034A1 Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
11/15/2007WO2007131020A2 Constrained compounds as cgrp-receptor antagonists
11/15/2007WO2007131016A2 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
11/15/2007WO2007131012A1 12-aryl or heteroaryl prostaglandin analogs
11/15/2007WO2007130982A2 Aqueous antiseptic solution and compatible anionic dye for staining skin
11/15/2007WO2007130981A2 Aqueous antiseptic solution and compatible cationic dye for staining skin
11/15/2007WO2007130945A1 A sustained-release intraocular implant comprising a vasoactive agent
11/15/2007WO2007130927A2 Condensed tricyclic compounds as cgrp-receptor antagonists
11/15/2007WO2007130902A2 Therapeutic cyclopentane derivatives
11/15/2007WO2007130898A1 TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1
11/15/2007WO2007130886A2 Nutritional supplement and use thereof
1 ... 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 ... 7860